ImmunoGen, Inc. announced that the European Medicines Agency has accepted the Marketing Authorization Application for mirvetuximab soravtansine for the treatment of patients with folate receptor alpha -positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.
